2022
Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2020
Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT).
Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT). Journal Of Clinical Oncology 2020, 38: e17052-e17052. DOI: 10.1200/jco.2020.38.15_suppl.e17052.Peer-Reviewed Original ResearchNonseminomatous germ cell tumorsRetroperitoneal lymph node dissectionLymph node countOverall survivalLN countStage IPrimary retroperitoneal lymph node dissectionTesticular nonseminomatous germ cell tumorsMultivariate analysisClinical stage ILymph node dissectionNational Cancer DatabaseSingle-center studyKaplan-Meier methodGerm cell tumorsNode countPT2 diseaseNode dissectionAnalytic cohortFavorable survivalCenter studyCell tumorsCancer DatabaseTherapeutic implicationsAcademic centersAccuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.
Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsPrimary retroperitoneal lymph node dissectionCS I patientsNational Cancer DatabaseI patientsClinical stageOverall survivalClinical stagingTesticular nonseminomatous germ cell tumorsLymph node dissectionQuarter of patientsKaplan-Meier methodNodal disease burdenGerm cell tumorsUpstaging of diseaseCS1 patientsPathologic nodalPN3 diseasePrior chemotherapyNode dissectionIIA patientsMeier methodClinical outcomesTesticular cancer
2019
Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionOverall survival rateTesticular seminomaSurvival rateOverall survivalClinical stagePC settingsUnderwent retroperitoneal lymph node dissectionComprehensive community cancer programsFive-year overall survivalNational Cancer DatabaseCommunity cancer programsFirst-line treatmentLow-volume diseaseLymph node dissectionKaplan-Meier methodSurvival dataAvailable survival dataMajority of menNonseminoma histologyPrior chemotherapyNode dissectionSeminoma patientsFinal cohortOngoing trials
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2017
Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer
Parikh R, Byun J, Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. The Prostate 2017, 77: 559-572. PMID: 28093791, DOI: 10.1002/pros.23294.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMetastatic prostate cancerLocal therapyOverall survivalProstate cancerRadiation therapyMultivariable Cox proportional hazards modelsLower co-morbidity scoreFive-year overall survivalCox proportional hazards modelAcademic/research programCo-morbidity scoreSuperior overall survivalNode-negative statusProspective clinical trialsKaplan-Meier methodLower T stagePatterns of careProportional hazards modelPropensity-score matchingPrimary diseaseT stageMedicare insuranceGleason scoreCancer Database
2015
Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification tool
2011
Three-gene signature predicts disease progression of non-muscle invasive bladder cancer.
Jeong P, Ha Y, Cho I, Yun S, Yoo E, Kim I, Choi Y, Moon S, Kim W. Three-gene signature predicts disease progression of non-muscle invasive bladder cancer. Oncology Letters 2011, 2: 679-684. PMID: 22848249, PMCID: PMC3406413, DOI: 10.3892/ol.2011.309.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerThree-gene signatureInvasive bladder cancerBladder cancerProgression of NMIBCThree-gene risk signatureMultivariate Cox regression modelMultivariate Cox regression analysisHigh-risk signaturePrevious study populationCox regression analysisKaplan-Meier methodCox regression modelKaplan-Meier estimatesBladder tumor progressionIndependent predictorsPrognostic valueDisease progressionTreatment outcomesClinical gradeRisk signatureStudy populationRisk scoreNew casesTumor progression